BioSpace News Archive

Evelo Biosciences, Inc. today announced data for EDP1815, the Company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis.

George Medicines today announced that its proprietary triple low-dose combination pill, GMRx2, will be trialed in UK patients with high blood pressure (hypertension), in a collaboration with ICTU Global, an Academic Clinical Research Organisation at Imperial College London.

Seegene to export COVID-19 test that detects COVID-19 and Omicron along with its Master Assay that distinguishes between COVID-19 and other respiratory viruses.

ASSA ABLOY has entered into an agreement to acquire Vigil Health Solutions Inc. (“Vigil”), a leader in innovative call systems and resident monitoring solutions for senior living.

Enhertu Granted Priority Review in the US for Patients With HER2-Positive Metastatic Breast Cancer Treated With a Prior Anti-HER2-Based Regimen.

Today, SparX announced that the FDA has approved their IND application for its organically developed anti-claudin18.2 antibody, SPX-101.

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common Share”) for the month of January 2022, which is payable on February 15, 2022 to shareholders of record at the close of business on January 31, 2022.

Company has completed the Phase 1 Clinical Trial for its INV-202 molecule.

Botanical Solution Inc has successfully closed $6.1 million in a Series A round led by Palo Alto based VC Firm, Otter Capital.

Aura PTx analyzes degraded excipients in protein therapeutics, and Aura+ is an all-in-one drug product quality tool for mAb, cell, and gene therapy.